Padcev significantly improved overall survival in patients with unresectable or metastatic urothelial carcinoma, especially in the chemo/ICI/Padcev group. Skin-related side effects were linked to ...
Enfortumab vedotin-ejfv and pembrolizumab show superior PFS and OS compared to chemotherapy in urothelial carcinoma. The combination therapy's benefits are consistent across subgroups, including ...
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results